Accenture buys Paris and New York based consultancy Bionest

03 February 2023 2 min. read

Accenture has bolstered its capabilities in the life sciences sector with the acquisition of Bionest, a management consultancy with nearly 50 staff in Paris and New York.

Founded in 2003 in Paris, Bionest is a management consulting firm dedicated to helping biopharma organisations across areas including market entry, regulatory, go-to-market and commercials, operating model design, and partnerships, with a focus on the precision medicine, diagnostics, oncology, cell & gene therapy, and rare disease segments.

Welcoming the 46-strong team from Bionest to the firm, Accenture senior managing director Brad Michel said: “The addition of their highly skilled team of experts expands our capabilities and will support our clients in bringing therapeutics to patients faster and more efficiently.”

Accenture buys Paris and New York based consultancy Bionest

As part of the integration, Bionest will join Accenture Strategy, the group’s consulting wing, as well as the Life Sciences practice, across offices in France and the United States.

“Complex areas of science require novel thinking when it comes to how businesses consider their go-to-market strategy,” said Rachel Laing, Bionest leader and managing director. “By joining Accenture, we’ll be able to bring new capabilities to our clients through strategy development and operational execution in some of the most exciting areas of science.”

Melinda Kutzing, fellow leader and managing director at Bionest, added that the move comes at a time of growing complexity for biopharma organisations. “They must juggle increasingly complex commercialisation challenges, patient access issues, and a changing regulatory and economic environment to achieve that growth.”

As a result, Kutzing said, biopharma companies must constantly assess their go-to-market strategy to maintain a competitive edge. This is where the joining of forces comes in – “together with Accenture’s deep industry capabilities and global network, Bionest will be better able to serve the goals of its clients.”

Bionest’s clientele include both major established and emerging pharmaceutical and biotechnology brands, chiefly in North America and Europe.

The deal continues a long streak of consulting acquisitions in the life sciences sector.

In 2022, Bain & Company bought a minority stake in Trinity Life Sciences, Sia Partners purchased Latham BioPharm Group, while BDO acquired life sciences specialist AdaptaLogix, among others. In 2021, Oliver Wyman bolted-on Huron’s life sciences strategy practice in the United States.